EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus

Khalid M Dousa iD, Eunjeong Shin iD, Sebastian G Kurz, Mark Plummer, Mary Nantongo iD, Christopher R Bethel, Magdalena A Taracila iD, David C Nguyen, Barry N Kreiswith, Charles L Daley, Kenneth E Remy, Steven M Holland und 1 weitere

mBio · 2024

DOI: 10.1128/mbio.00609-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Khalid M Dousa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Anti-Bacterial Agents, Drug Synergism, Microbial Sensitivity Tests. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Veterans Affairs (VA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus ( Mab ) affects patients with immunosuppression or underlying structural lung diseases such as cystic fibrosis (CF). Additionally, Mab poses clinical challenges due to its resistance to multiple antibiotics. Herein, we investigated the synergistic effect of dual β-lactams [sulopenem and cefuroxime (CXM)] or the combination of sulopenem and CXM with β-lactamase inhibitors [BLIs—avibactam (AVI) or durlobactam (DUR)]. The sulopenem-CXM combination yielded low minimum inhibitory concentration (MIC) values for 54 clinical Mab isolates and ATCC19977 (MIC 50 and MIC 90 ≤0.25 µg/mL). Similar synergistic effects were observed in time-kill studies conducted at concentrations achievable in clinical settings. Sulopenem-CXM outperformed monotherapy, yielding ~1.5 Log 10 CFU/mL reduction during 10 days. Addition of BLIs enhanced this antibacterial effect, resulting in an additional reduction of CFUs (~3 Log 10 for sulopenem-CXM and AVI and ~4 Log 10 for sulopenem-DUR). Exploration of the potential mechanisms of the synergy focused on their interactions with L,D-transpeptidases (Ldts; Ldt Mab1 –Ldt Mab4 ), penicillin-binding-protein B (PBP B), and D,D-carboxypeptidase (DDC). Acyl complexes, identified via mass spectrometry analysis, demonstrated the binding of sulopenem with Ldt Mab2 –Ldt Mab4 , DDC, and PBP B and CXM with Ldt Mab2 and PBP B. Molecular docking and mass spectrometry data suggest the formation of a covalent adduct between sulopenem and Ldt Mab2 after the nucleophilic attack of the cysteine residue at the β-lactam carbonyl carbon, leading to the cleavage of the β-lactam ring and the establishment of a thioester bond linking the Ldt Mab2 with sulopenem. In conclusion, we demonstrated the biochemical basis of the synergy of sulopenem-CXM with or without BLIs. These findings potentially broaden the selection of oral therapeutic agents to combat Mab . IMPORTANCE Treating infections from Mycobacterium abscessus (Mab), particularly those resistant to common antibiotics like macrolides, is notoriously difficult, akin to a never-ending struggle for healthcare providers. The rate of treatment failure is even higher than that seen with multidrug-resistant tuberculosis. The role of combination β-lactams in inhibiting L,D-transpeptidation, the major peptidoglycan crosslink reaction in Mab, is an area of intense investigation, and clinicians have utilized this approach in the treatment of macrolide-resistant Mab, with reports showing clinical success. In our study, we found that cefuroxime and sulopenem, when used together, display a significant synergistic effect. If this promising result seen in lab settings, translates well into real-world clinical effectiveness, it could revolutionize current treatment methods. This combination could either replace the need for more complex intravenous medications or serve as a “step down” to an oral medication regimen. Such a shift would be much easier for patients to manage, enhancing their comfort and likelihood of sticking to the treatment plan, which could lead to better outcomes in tackling these tough infections. Our research delved into how these drugs inhibit cell wall synthesis, examined time-kill data and binding studies, and provided a scientific basis for the observed synergy in cell-based assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusAnti-Bacterial AgentsDrug SynergismMicrobial Sensitivity TestsCefuroximeHumansMycobacterium Infections, Nontuberculousbeta-Lactamase InhibitorsMolecular Docking SimulationProhibitins

Stichwörter der Autor:innen

Mycobacterium abscessusdual β-lactamsoral carbapenemsulopenem

Substanzen

Anti-Bacterial AgentsCefuroximebeta-Lactamase InhibitorsPHB2 protein, humanProhibitins

Autor:innen und Institutionen

  • Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Department of Medicine, University of Tübingen, Tübingen, Germany.
  • Yale Center for Molecular Discovery, Yale University, New Haven, Connecticut, USA.
  • Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA.

ORCID-Profile: Khalid M Dousa, Eunjeong Shin, Mary Nantongo, Magdalena A Taracila, Robert A Bonomo

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • U.S. Department of Veterans Affairs (VA)
  • BLRD VA
  • FIC NIH HHS

Zitieren

APA

Dousa, K. M., Shin, E., Kurz, S. G., Plummer, M., Nantongo, M., Bethel, C. R., Taracila, M. A., Nguyen, D. C., Kreiswith, B. N., Daley, C. L., Remy, K. E., Holland, S. M., & Bonomo, R. A. (2024). Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. mBio. https://doi.org/10.1128/mbio.00609-24

Vancouver

Dousa KM, Shin E, Kurz SG, Plummer M, Nantongo M, Bethel CR, et al. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. mBio. 2024. doi:10.1128/mbio.00609-24

BibTeX
@article{Dousa2024,
  author = {Dousa, Khalid M and Shin, Eunjeong and Kurz, Sebastian G and Plummer, Mark and Nantongo, Mary and Bethel, Christopher R and Taracila, Magdalena A and Nguyen, David C and Kreiswith, Barry N and Daley, Charles L and Remy, Kenneth E and Holland, Steven M and Bonomo, Robert A},
  title = {Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.00609-24}
}
Kostenlos starten →